{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:46:46Z","timestamp":1777704406211,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A phase II trial (MO-Ped; NCT03442985) assessed palovarotene in pediatric patients with multiple hereditary exostosis (MHE). Patients aged\u2009\u2264\u200914 years with MHE were randomized 1:1:1 to placebo, palovarotene 2.5\u00a0mg, or palovarotene 5.0\u00a0mg daily. Due to concerns of premature physeal closure (PPC), a partial clinical hold was instituted, followed by trial termination. The primary efficacy endpoint was the annualized rate of new osteochondromas (OCs). Safety was assessed. Overall, 193 patients received\u2009\u2265\u20091 dose of palovarotene or placebo. Due to trial termination, no patients completed planned treatment. Prior to 06 December 2019 (patients notified of clinical hold and treatment stopped), 30 patients completed Month 12 efficacy imaging. No significant differences in the annualized rate of new OCs, or change from baseline in volume of OCs or OC cartilage, were observed between treatment groups. The adverse event profile was consistent with systemic retinoids. There was no evidence of an effect of palovarotene on linear growth and no cases of PPC. Overall, palovarotene showed no clear efficacy signal in MHE, resulting in a non-favorable benefit-risk profile. Interpretation of results was limited by the reduced treatment duration and smaller than expected cohort. The trial yielded important data on the natural history of MHE.<\/jats:p>\n                  <jats:p>\n                    <jats:italic>Trial registration<\/jats:italic>\n                    : NCT03442985 (first posted 22 February\u00a02018)\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-22554-6","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:42:06Z","timestamp":1762281726000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Palovarotene for patients with multiple hereditary exostosis: results of MO-Ped, a terminated, randomized, placebo-controlled, double-blind phase 2 trial"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3658-1209","authenticated-orcid":false,"given":"Luca","family":"Sangiorgi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0485-907X","authenticated-orcid":false,"given":"Ernest U.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5821-1267","authenticated-orcid":false,"given":"Fei","family":"Shih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Strahs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9190-6083","authenticated-orcid":false,"given":"David S.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"issue":"7","key":"22554_CR1","doi-asserted-by":"publisher","first-page":"986","DOI":"10.2106\/00004623-199407000-00005","volume":"76","author":"GA Schmale","year":"1994","unstructured":"Schmale, G. A., Conrad, E. U. & Raskind, W. H. The natural history of hereditary multiple exostoses. J. Bone Jt. Surg. 76(7), 986\u2013992 (1994).","journal-title":"J. Bone Jt. Surg."},{"issue":"4","key":"22554_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1101\/gr.7.4.359","volume":"7","author":"GA Clines","year":"1997","unstructured":"Clines, G. A., Ashley, J. A., Shah, S. & Lovett, M. The structure of the human multiple exostoses 2 gene and characterization of homologs in mouse and Caenorhabditis elegans. Genome Res. 7(4), 359\u2013367 (1997).","journal-title":"Genome Res."},{"issue":"2","key":"22554_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.21873\/invivo.12308","volume":"35","author":"K Tepelenis","year":"2021","unstructured":"Tepelenis, K. et al. Osteochondromas: An updated review of epidemiology, pathogenesis, clinical presentation, radiological features and treatment options. In Vivo 35(2), 681\u2013691 (2021).","journal-title":"In Vivo"},{"issue":"4","key":"22554_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jbmr.3341","volume":"33","author":"T Inubushi","year":"2018","unstructured":"Inubushi, T., Lemire, I., Irie, F. & Yamaguchi, Y. Palovarotene inhibits osteochondroma formation in a mouse model of multiple hereditary exostoses. J. Bone Miner. Res. 33(4), 658\u2013666 (2018).","journal-title":"J. Bone Miner. Res."},{"issue":"3","key":"22554_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1007\/s11914-017-0355-2","volume":"15","author":"P Maurizio","year":"2017","unstructured":"Maurizio, P. Hereditary multiple exostoses: New insights into pathogenesis, clinical complications and potential treatments. Curr. Osteoporos. Rep. 15(3), 142\u2013152 (2017).","journal-title":"Curr. Osteoporos. Rep."},{"issue":"10","key":"22554_CR6","doi-asserted-by":"publisher","first-page":"16362","DOI":"10.1002\/jcb.29155","volume":"120","author":"C Yang","year":"2019","unstructured":"Yang, C., Zhang, R., Lin, H. & Wang, H. Insights into the molecular regulatory network of pathomechanisms in osteochondroma. J. Cell. Biochem. 120(10), 16362\u201316369 (2019).","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"22554_CR7","first-page":"351","volume":"16","author":"L Solomon","year":"1964","unstructured":"Solomon, L. Hereditary multiple exostosis. Am. J. Hum. Genet. 16(3), 351\u2013363 (1964).","journal-title":"Am. J. Hum. Genet."},{"key":"22554_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/ORR.S183979","volume":"11","author":"A D\u2019Arienzo","year":"2019","unstructured":"D\u2019Arienzo, A., Andreani, L., Sacchetti, F., Colangeli, S. & Capanna, R. Hereditary multiple exostoses: Current insights. Orthopedic Res. Rev. 11, 199\u2013211 (2019).","journal-title":"Orthopedic Res. Rev."},{"key":"22554_CR9","doi-asserted-by":"crossref","unstructured":"Mavrogenis, A. F., Papagelopoulos, P. J. & Soucacos, P. N. Skeletal osteochondromas revisited. Orthopedics 31(10) (2008).","DOI":"10.3928\/01477447-20110525-01"},{"key":"22554_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1750-1172-3-3","volume":"3","author":"JV Bovee","year":"2008","unstructured":"Bovee, J. V. Multiple osteochondromas. Orphanet J. Rare Dis. 3, 3 (2008).","journal-title":"Orphanet J. Rare Dis."},{"issue":"4","key":"22554_CR11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/jmg.28.4.262","volume":"28","author":"RC Hennekam","year":"1991","unstructured":"Hennekam, R. C. Hereditary multiple exostoses. J. Med. Genet. 28(4), 262\u2013266 (1991).","journal-title":"J. Med. Genet."},{"issue":"7","key":"22554_CR12","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s11999-015-4134-z","volume":"473","author":"CM Czajka","year":"2015","unstructured":"Czajka, C. M. & DiCaprio, M. R. What is the proportion of patients with multiple hereditary exostoses who undergo malignant degeneration?. Clin. Orthop. Relat. Res. 473(7), 2355\u20132361 (2015).","journal-title":"Clin. Orthop. Relat. Res."},{"issue":"4","key":"22554_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/1897-4287-2-4-161","volume":"2","author":"L Hameetman","year":"2004","unstructured":"Hameetman, L., Bovee, J. V., Taminiau, A. H., Kroon, H. M. & Hogendoorn, P. C. Multiple osteochondromas: Clinicopathological and genetic spectrum and suggestions for clinical management. Hered. Cancer Clin. Pract. 2(4), 161\u2013173 (2004).","journal-title":"Hered. Cancer Clin. Pract."},{"issue":"8","key":"22554_CR14","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1302\/0301-620X.85B8.14059","volume":"85","author":"F Bottner","year":"2003","unstructured":"Bottner, F. et al. Surgical treatment of symptomatic osteochondroma. A three- to eight-year follow-up study. J. Bone Joint Surg. Br. 85(8), 1161\u20131165 (2003).","journal-title":"J. Bone Joint Surg. Br."},{"key":"22554_CR15","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/00003086-198902000-00026","volume":"239","author":"HA Peterson","year":"1989","unstructured":"Peterson H.A. Multiple hereditary osteochondromata. Clin. Orthop. Relat. Res. 239, 222\u2013230 (1989).","journal-title":"Clin. Orthop. Relat. Res."},{"key":"22554_CR16","unstructured":"FDA. Sohonos highlights of prescribing information. Accessed August 2023. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215559s000lbl.pdf."},{"issue":"11","key":"22554_CR17","first-page":"1243","volume":"10","author":"M Hind","year":"2009","unstructured":"Hind, M. & Stinchcombe, S. Palovarotene, a novel retinoic acid receptor gamma agonist for the treatment of emphysema. Curr. Opin. Investig. Drugs 10(11), 1243\u20131250 (2009).","journal-title":"Curr. Opin. Investig. Drugs"},{"issue":"3","key":"22554_CR18","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/jbmr.4762","volume":"38","author":"RJ Pignolo","year":"2023","unstructured":"Pignolo, R. J. et al. Reduction of new heterotopic ossification (HO) in the open-label, phase 3 MOVE trial of palovarotene for fibrodysplasia ossificans progressiva (FOP). J. Bone Miner. Res. 38(3), 381\u2013394 (2023).","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"22554_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s13318-023-00856-2","volume":"48","author":"R Marino","year":"2023","unstructured":"Marino, R., Dube, L., Ogier, J. & Le Quan Sang, K.-H. The pharmacokinetic profile of palovarotene: An open-label phase I trial investigating the effect of food and potential for drug\u2013drug interaction in healthy participants. Eur. J. Drug Metab. Pharmacokinet. 48(6), 691\u2013707 (2023).","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"22554_CR20","unstructured":"The Drug and Health Product Register GoC. SOHONOS product monograph. Accessed August 2023. Available at: https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/16\/2024\/12\/02164310\/PM-Sohonos-EN-20Nov2024.pdf."},{"key":"22554_CR21","unstructured":"ClinicalTrials.gov. NCT03442985. Accessed June 2023. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03442985."},{"key":"22554_CR22","unstructured":"Ipsen. Ipsen initiates partial clinical hold for palovarotene IND120181 and IND135403 studies. Accessed June 2023. Available at: https:\/\/www.ipsen.com\/press-releases\/ipsen-initiates-partial-clinical-hold-for-palovarotene-ind120181-and-ind135403-studies\/."},{"key":"22554_CR23","unstructured":"ClinicalTrials.gov. NCT04133285. Registry of multiple osteonchodromas (REM). Accessed June 2023. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04133285."},{"issue":"1","key":"22554_CR24","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/BPB.0000000000000010","volume":"23","author":"CE Hill","year":"2014","unstructured":"Hill, C. E., Boyce, L. & van der Ploeg, I. D. Spontaneous resolution of a solitary osteochondroma of the distal femur: A case report and review of the literature. J. Pediatr. Orthop. B 23(1), 73\u201375 (2014).","journal-title":"J. Pediatr. Orthop. B"},{"issue":"3","key":"22554_CR25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/BPO.0b013e31820fc676","volume":"31","author":"AM Passanise","year":"2011","unstructured":"Passanise, A. M., Mehlman, C. T., Wall, E. J. & Dieterle, J. P. Radiographic evidence of regression of a solitary osteochondroma: A report of 4 cases and a literature review. J. Pediatr. Orthop. 31(3), 312\u2013316 (2011).","journal-title":"J. Pediatr. Orthop."},{"key":"22554_CR26","doi-asserted-by":"publisher","first-page":"115499","DOI":"10.1016\/j.bone.2020.115499","volume":"139","author":"M Mordenti","year":"2020","unstructured":"Mordenti, M. et al. The natural history of multiple osteochondromas in a large Italian cohort of pediatric patients. Bone 139, 115499 (2020).","journal-title":"Bone"},{"issue":"11","key":"22554_CR27","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1002\/ajmg.a.62470","volume":"185","author":"M Mordenti","year":"2021","unstructured":"Mordenti, M. et al. The rizzoli multiple osteochondromas classification revised: Describing the phenotype to improve clinical practice. Am. J. Med. Genet. A 185(11), 3466\u20133475 (2021).","journal-title":"Am. J. Med. Genet. A"},{"issue":"6","key":"22554_CR28","doi-asserted-by":"publisher","first-page":"e21107","DOI":"10.1371\/journal.pone.0021107","volume":"6","author":"H Fritz","year":"2011","unstructured":"Fritz, H. et al. Vitamin A and retinoid derivatives for lung cancer: A systematic review and meta analysis. PLoS One 6(6), e21107 (2011).","journal-title":"PLoS One"},{"issue":"1","key":"22554_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjd.15668","volume":"178","author":"IA Vallerand","year":"2018","unstructured":"Vallerand, I. A. et al. Efficacy and adverse events of oral isotretinoin for acne: A systematic review. Br. J. Dermatol. 178(1), 76\u201385 (2018).","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"22554_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/pde.14408","volume":"38","author":"AL Zaenglein","year":"2021","unstructured":"Zaenglein, A. L. et al. Consensus recommendations for the use of retinoids in ichthyosis and other disorders of cornification in children and adolescents. Pediatr Dermatol. 38(1), 164\u2013180 (2021).","journal-title":"Pediatr Dermatol."},{"key":"22554_CR31","doi-asserted-by":"publisher","first-page":"759129","DOI":"10.3389\/fgene.2021.759129","volume":"12","author":"E Bukowska-Olech","year":"2021","unstructured":"Bukowska-Olech, E. et al. Hereditary multiple exostoses-a review of the molecular background, diagnostics, and potential therapeutic strategies. Front. Genet. 12, 759129 (2021).","journal-title":"Front. Genet."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22554-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22554-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T18:42:09Z","timestamp":1762281729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22554-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22554"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22554-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LS, EUC and DSF: no conflicts of interest to declare. FS and AS: Employees and stockholders (received as part of their employee compensation) of Ipsen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The trial was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"38563"}}